At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALT Altimmune, Inc.
Post-Market Trading 03-13 16:24:42 EDT
5.20
-0.35
-6.31%
盘后5.30
+0.10+1.92%
16:23 EDT
High5.62
Low5.14
Vol2.89M
Open5.46
D1 Closing5.55
Amplitude8.65%
Mkt Cap400.47M
Tradable Cap366.38M
Total Shares77.01M
T/O15.40M
T/O Rate4.09%
Tradable Shares70.46M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Altimmune Inc - Phase 2 AUD Trial for Pemvidutide Expected in Q2 2025
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.